P21WAF1 and tumourigenesis: 20 Years after

Noel A. Warfel, Wafik S. El-Deiry

Research output: Contribution to journalReview articlepeer-review

244 Scopus citations


PURPOSE OF REVIEW: This review provides an overview of the structure, regulation and physiological functions of p21, the product of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene, with a focus on its dual role in promoting and repressing biological processes that are hallmarks of tumourigenesis. RECENT FINDINGS: Recent work has provided a better understanding of the molecular mechanisms of how oncogenic signalling pathways influence p21 expression. In response to cellular stimuli, p21 expression is tightly regulated at transcriptional and post-translational levels through mechanisms involving RNA stabilization, phosphorylation and ubiquitination. As a result, growing evidence reveals that several important tumour suppressor and oncogenic signalling pathways alter p21 expression to elicit their effects on cell cycle progression and survival. Thus, p21 expression can both promote and inhibit tumourigenic processes, depending on the cellular context. SUMMARY: Since its discovery, it has become increasingly clear that p21 can function as both a classical tumour suppressor and an oncogene. In order to effectively utilize p21 as a therapeutic target, it will be necessary to design therapeutic strategies that preferentially block the ability of p21 to promote senescence, stem cell renewal and cyclin/CDK activation, while leaving its tumour suppressive functions intact.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalCurrent Opinion in Oncology
Issue number1
StatePublished - Jan 2013
Externally publishedYes


  • Cell cycle
  • Cyclin-dependent kinase
  • p21
  • Wild-type p53-activated fragment 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'P21WAF1 and tumourigenesis: 20 Years after'. Together they form a unique fingerprint.

Cite this